Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.56 |
| ▸ | HMGCR | P04035 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | PPARD | Q03181 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701316 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL7382880 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL6539108 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL3972155 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL3980051 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1702085 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL374773 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1654498 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1401237 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL7292218 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934567-B9 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-08-22 | — | — | EP | claimed |
| EP-2934567-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-05-09 | — | — | EP | claimed |
| EP-2934568-B1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-10-18 | — | — | EP | claimed |
| EP-2906595-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-08-16 | — | — | EP | claimed |
| EP-2934566-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-06-21 | — | — | EP | claimed |
| US-9181305-B2 | Exendin-4 peptide analogues | SANOFI (FR) | 2015-11-10 | — | — | US | claimed |
| EP-2435061-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT | Amylin Pharmaceuticals, Inc. (US) | 2012-04-04 | — | — | EP | claimed |
| WO-2011156407-A2 | GLP-1 RECEPTOR AGONISTS TO TREAT PANCRE-ATITIS | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | claimed |
| WO-2010138671-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | WO | claimed |
| US-7541430-B2 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | claimed |
| US-20070244054-A1 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2007-10-18 | — | — | US | claimed |
| EP-1625158-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | claimed |
| WO-2004099246-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| US-6268343-B1 | HUMAN GLUCAGON-LIKE PEPTIDE-1; MORE PROTRACTED PROFILE OF ACTION THAN THE PARENT PEPTIDES; TREATING DIABETES AND OBESITY; Liraglutide | NOVO NORDISK A/S (DK) | 2001-07-31 | — | — | US | claimed |
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-111848778-B | Teriparatide analogues | 上海医药工业研究院 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023204170-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT, FOR LUNG INFLAMMATION AND FIBROSIS, CONTAINING COMPOUND HAVING MMP2 INHIBITORY ACTIVITY AS ACTIVE INGREDIENT | 大正製薬株式会社 | 2023-10-26 | — | — | WO | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | MMP2, MMP26, MMP25 | TSHR 1247/4885LMNA 1711/4885NFKB1 2212/4885 |
| US-20070244054-A1 | Peptides for use in treating obesity | NPY4R, GLP1R, NPY1R | TSHR 296/4885LMNA 3088/4885NFKB1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.